Arvinas (ARVN)
Nasdaq Market Open
Arvinas, Inc is a clinical-stage biotechnology company developing medicines based on targeted protein degradation. Rather than simply blocking the activity of a disease-related protein, Arvinas designs therapies intended to remove the protein from cells by directing it to the body’s natural disposal machinery. Its work is built around PROTAC, or proteolysis-targeting chimera, technology, a platform that links a target protein to an E3 ubiquitin ligase so the protein can be tagged and degraded by the proteasome.
The company applies this approach mainly in oncology and neuroscience, where abnormal or misregulated proteins can drive disease. Its pipeline includes investigational candidates designed to address targets that have historically been difficult to inhibit with conventional small molecules. Vepdegestrant, formerly ARV-471, is one of its most closely watched programmes and is being developed as an estrogen receptor degrader for hormone receptor-positive breast cancer. Arvinas also advances additional candidates across cancer and neurological indications, including programmes referenced as ARV-102, ARV-806, ARV-393, and ARV-027.
Arvinas operates in a high-risk, research-intensive segment of the healthcare market. Its value depends on clinical trial progress, safety and efficacy results, regulatory outcomes, intellectual property protection, and the ability to manufacture and commercialize novel degrader medicines. The company is distinctive because it is one of the pioneers of the targeted protein degradation field, seeking to turn the cell’s own quality-control system into a therapeutic tool for diseases where disease-causing proteins are central to pathology.
Last updated
- Market Cap
- 496.81M
- P/E
- —
- P/FCF
- —
- P/S
- 5.56
- Enterprise Value
- 409.81M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 395 WINCHESTER AVE, NEW HAVEN, CT, 06511
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
New nanoparticle technology offers hope for hard-to-treat diseases
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas to Participate in Upcoming Investor Conferences
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Kirby McInerney LLP Announces Investigation of Claims Against FTI Consulting, Inc. (FCN) on Behalf of Investors
Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 496.81M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 409.81M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.28
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 5.56
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.64
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 4.58
- EPS
- -3.43
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -256.9M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -57.21%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -34.18%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 5.44
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 5.44
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.75
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 899.18K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 7.7
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 15.6M | 9.5M | 41.9M | 22.4M | 188.8M |
| Gross profit | 15.6M | 9.5M | 41.9M | 22.4M | 188.8M |
| Operating income | -63.8M | -74.6M | -43.8M | -71.5M | 71.4M |
| EBITDA | -62.8M | -69.6M | -43M | -74M | 75.4M |
| Net income | -57.6M | -67.4M | -35.1M | -61.2M | 82.9M |
| Basic EPS | -0.9 | -0.96 | -0.48 | -0.84 | 1.14 |
| Diluted EPS | -0.9 | -0.96 | -0.48 | -0.84 | 1.14 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 647.5M | 717.9M | 844.3M | 909.3M | 1B |
| Total liabilities | 260.7M | 284M | 279.9M | 300M | 341M |
| Total equity | 386.8M | 433.9M | 564.4M | 609.3M | 660.1M |
| Cash & equivalents | 87.3M | 142.9M | 101.5M | 114.9M | 81M |
| Current assets | 630.7M | 700.7M | 826.3M | 889.5M | 979.7M |
| Current liabilities | 115.9M | 142.5M | 144.9M | 157.8M | 214M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -69.2M | -30.4M | -59.1M | -95.4M | -88.9M |
| Investing cash flow | 13.7M | 145.8M | 63.5M | 128.8M | 69.5M |
| Financing cash flow | -100K | -74M | -17.8M | 500K | -100K |
| Change in cash | -55.6M | 41.4M | -13.4M | 33.9M | -19.5M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — ARVINAS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 8-K — ARVINAS, INC. | View Filing | |
| edgar index | 8-K — ARVINAS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — ARVINAS, INC. | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| form 4 | Form 4 — Berkowitz Noah | View Filing | |
| form 4 | Form 4 — Cacace Angela M | View Filing | |
| form 4 | Form 4 — Loomis David K | View Filing | |
| form 4 | Form 4 — Saik Andrew | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 8-K — ARVINAS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — ARVINAS, INC. | View Filing | |
| edgar index | DEFA14A — ARVINAS, INC. | View Filing | |
| edgar index | ARS — ARVINAS, INC. | View Filing | |
| edgar index | SCHEDULE 13G — ARVINAS, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 8-K — ARVINAS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Berkowitz Noah | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 4/A — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| form 4 | Form 4 — Morrison Briggs | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| form 4 | Form 4 — Houston John G | View Filing | |
| form 4 | Form 4 — Houston John G | View Filing | |
| form 4 | Form 4 — Houston John G | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| form 4 | Form 4 — Saik Andrew | View Filing | |
| form 4 | Form 4 — Saik Andrew | View Filing | |
| form 4 | Form 4 — Berkowitz Noah | View Filing | |
| form 4 | Form 4 — Berkowitz Noah | View Filing | |
| form 4 | Form 4 — Cacace Angela M | View Filing | |
| form 4 | Form 4 — Cacace Angela M | View Filing | |
| form 4 | Form 4 — Loomis David K | View Filing | |
| form 4 | Form 4 — Loomis David K | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 4 — ARVINAS, INC. | View Filing | |
| edgar index | 8-K — ARVINAS, INC. | View Filing | |
| edgar index | 10-K — ARVINAS, INC. | View Filing | |
| edgar index | S-8 — ARVINAS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| edgar index | 144 — ARVINAS, INC. | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| form 4 | Form 4 — Teel Randy | View Filing | |
| form 4 | Form 4 — Cacace Angela M | View Filing |